Mary S. Brady

Dr. Mary S. Brady


Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2005 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
WHWilliam G. Hawkins
William G. Hawkins
KBKlaus J. Busam
Klaus J. Busam
LBLeah Ben-Porat
Leah Ben-Porat
KPKatherine S. Panageas
Katherine S. Panageas
DCDaniel G. Coit
Daniel G. Coit
MBMary S. Brady
Mary S. Brady

15 November 2007 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
KMKatherine T. Morris
Katherine T. Morris
KBKlaus J. Busam
Klaus J. Busam
SBSuzannah Bero
Suzannah Bero
APAmi Patel
Ami Patel
MBMary S. Brady
Mary S. Brady

15 February 2006 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
MBMary S. Brady
Mary S. Brady
TATimothy Akhurst
Timothy Akhurst
KSKathryn Spanknebel
Kathryn Spanknebel
SHSusan Hilton
Susan Hilton
MGMithat Gonen
Mithat Gonen
SLSteven Larson
Steven Larson

21 June 2006 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
MBMary S. Brady
Mary S. Brady
KBKaren Brown
Karen Brown
APAmi Patel
Ami Patel
CFCharles Fisher
Charles Fisher
WMWill Marx
Will Marx

28 January 2021 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
ASAlexander N. Shoushtari
Alexander N. Shoushtari
WCWalid K. Chatila
Walid K. Chatila
AAArshi Arora
Arshi Arora
FSFrancisco Sanchez-Vega
Francisco Sanchez-Vega
HKHavish S. Kantheti
Havish S. Kantheti
NSNikolaus Schultz
Nikolaus Schultz
Purpose: Cutaneous and unknown primary melanomas frequently harbor alterations that activate the MAPK pathway. Whether MAPK driver detection beyond BRAF V600 is clinically relevant in the checkpoint inhibitor era is unknown. Experimental Design: Patients with melanoma were prospectively offered tumor sequencing of 341–468 genes. Oncogenic alterations in 28 RTK-RAS-MAPK pathway genes were used to construct MAPK driver groups. Time to treatment failure (TTF) was determined for patients who received first-line programmed cell death protein 1 (PD-1) monotherapy, nivolumab plus ipilimumab, or subsequent genomically matched targeted therapies. A Cox proportional hazards model was constructed for TTF using driver group and clinical variables. Results: A total of 670 of 696 sequenced melanomas (96%) harbored an oncogenic RTK-RAS-MAPK pathway alteration; 33% had ≥1 driver. Nine driver groups varied by clinical presentation and mutational burden. TTF of PD-1 monotherapy (N = 181) varied by driver, with worse outcomes for NRAS Q61 and BRAF V600 versus NF1 or other alterations (median 4.2, 7.5, 22, and not reached; P < 0.0001). Driver group remained significant, independent of tumor mutational burden and clinical features. TTF did not vary by driver for nivolumab plus ipilimumab (N = 141). Among 172 patients with BRAF V600 wild-type melanoma who progressed on checkpoint blockade, 27 were treated with genomically matched therapy, and eight (30%) derived clinical benefit lasting ≥6 months. Conclusions: Targeted capture multigene sequencing can detect oncogenic RTK-RAS-MAPK pathway alterations in almost all cutaneous and unknown primary melanomas. TTF of PD-1 monotherapy varies by mechanism of ERK activation. Oncogenic kinase fusions can be successfully targeted in immune checkpoint inhibitor–refractory melanoma.

2 July 2003 in Cancer
Verified
Journal Article
Closed access
PDF file
BNBenjamin P. Negin
Benjamin P. Negin
ERElyn Riedel
Elyn Riedel
SOSusan A. Oliveria
Susan A. Oliveria
Marianne BerwickMarianne Berwick
Marianne Berwick
DCDaniel G. Coit
Daniel G. Coit
MBMary S. Brady
Mary S. Brady